Accessibility statement

Mark Sculpher
Professor and Director of CHE



Mark Sculpher is Professor of Health Economics and Director of the Centre. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU). He has been based at York University since 1997. 

Between 1988 and 1997, he worked at the Health Economics Research Group at Brunel University; during 1998 he was a visitor in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Canada.

Mark has worked on economic evaluations of a range of technologies including heart disease and various cancers. He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty. He has over 280 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the economic evaluation of health care programmes (OUP, 2015 with Drummond, Claxton, Torrance, and Stoddart) and Decision modelling for health economic evaluation (OUP, 2006 with Briggs and Claxton). He was also a member of the Second Panel on Cost-Effectiveness in Health and Medicine.

Mark was a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee (2004-8), the NICE Public Health Interventions Advisory Committee (2006-9) and the NICE Diagnostics Advisory Committee (2010-20). He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and was a member of the Methods Working Party for the 2008 update of this guidance. He was a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme (2007-10), the UK National Institute for Health Research (NIHR)/Medical Research Council (MRC) Methodology Research Panel (2008-11) and the MRC-NIHR Methodology Research Advisory Group (2016-20). He was a member of the NIHR Policy Research Programme‚Äôs Commissioning Panel (2011-14). Mark is a NIHR Senior Investigator (Emeritus) and is a former President of the International Society of Pharmacoeconomics and Outcomes Research.

Recent national and international advisory roles include the Singapore Agency for Care Effectiveness International Advisory Panel (2017-18); UK Health Select Committee Availability of Orkambi on the NHS inquiry (2018-19); Portuguese National Authority of Medicines and Health Products (2018-20).



  • Decision analytic modelling, analysis of uncertainty and heterogeneity, pharmaceutical policy, economic evaluation and decision making
  • Heart disease, cancer, medical devices, diagnostics, public health

Research group(s)





External activities


Editorial duties

Recent Presentations 

  • Maximising the policy-relevance of economic evaluation: recent methods advances and remaining challenges. Invited lecture at University of Cape Town, Cape Town, South Africa. February 2020.
  • Economic evaluation of new antibiotics: health still the focus. Virtual ISPOR. May 2020.
  • How do we assess the value of cancer drug optimization? International Summit on Interventional Pharmacoeconomics (virtual). July 2020.
  • The principles of value frameworks for decision-making in health. Invited talk for ISPOR South Africa (virtual). November 2020.
  • Evidence needs for evaluating predictive technologies. Talk at Academy of Medical Sciences FORUM workshop: Precision prevention for modifiable health risks: steps to achieving personalised preventative healthcare. December 2020.
Staff Photo for Mark Sculpher

Contact details

Mark Sculpher
Centre for Health Economics